© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Constantine S. Tam, MD, associate professor, Peter MacCallum Cancer Centre, discusses the phase III DUO trial, a randomized comparison of duvelisib versus ofatumumab (Arzerra) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia.